Maplight Therapeutics (NASDAQ:MPLT) Insider James Woodruff Lillie Sells 15,801 Shares

Key Points

• Insider James Woodruff Lillie sold about 51,707 shares of Maplight across May 4–6 (15,801 at $27.96, 11,095 at $28.20 and 24,811 at $28.76), generating roughly $1.47M in proceeds; the sales were made under a pre‑arranged Rule 10b5‑1 trading plan.
• Shares traded up to $29.04 (50‑day MA $22.60) and the company has a $1.24B market cap, but Maplight reported a Q1 EPS loss of -$2.47 versus a -$1.05 consensus, underscoring ongoing losses.
• Analyst coverage is broadly bullish with multiple Buy initiations/reaffirmations (HC Wainwright $45 target; consensus target ~$34.43), though some forecasts warn of continued cash‑burn and larger projected losses through 2026–27.

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider James Woodruff Lillie sold 15,801 shares of the company's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $27.96, for a total value of $441,795.96. Following the completion of the transaction, the insider directly owned 279,356 shares in the company, valued at approximately $7,810,793.76. The trade was a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.
• On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total transaction of $312,879.00.

Maplight Therapeutics Stock Performance

Shares of NASDAQ MPLT traded up $1.12 during trading on Wednesday, reaching $29.04. 267,979 shares of the company traded hands, compared to its average volume of 342,018. The company has a fifty day moving average price of $22.60. The firm has a market cap of $1.24 billion and a PE ratio of -0.73. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($1.42). As a group, equities analysts expect that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Trending Headlines about Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its "Buy" rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a "Buy" rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright's detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Institutional Trading of Maplight Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MPLT. Fcpm Iii Services B.V. purchased a new stake in Maplight Therapeutics in the fourth quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $49,154,000. Goldman Sachs Group Inc. purchased a new stake in Maplight Therapeutics in the 4th quarter valued at about $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics in the fourth quarter valued at about $17,060,000. Finally, 5AM Venture Management LLC acquired a new stake in shares of Maplight Therapeutics during the fourth quarter valued at about $16,687,000.

Wall Street Analysts Forecast Growth

MPLT has been the topic of a number of recent analyst reports. TD Cowen began coverage on Maplight Therapeutics in a research report on Tuesday, April 7th. They set a "buy" rating on the stock. HC Wainwright started coverage on shares of Maplight Therapeutics in a research report on Monday. They set a "buy" rating and a $45.00 price objective for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They issued a "buy" rating and a $35.00 target price on the stock. Wall Street Zen cut shares of Maplight Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Finally, Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a "sell (e)" rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.